### Highlights of This Issue 1693

#### SPECIAL FEATURES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1695</td>
<td>Metformin: A Therapeutic Opportunity in Breast Cancer</td>
<td>Ana M. Gonzalez-Angulo, Funda Meric-Bernstam</td>
</tr>
<tr>
<td>1701</td>
<td>Death Receptor Agonists as a Targeted Therapy for Cancer</td>
<td>Jeffrey Wiezorek, Pamela Holland, Jonathan Graves</td>
</tr>
<tr>
<td>1709</td>
<td>Phase I Clinical Trials: Overcoming Barriers</td>
<td>Susan E. Bates</td>
</tr>
<tr>
<td>1710</td>
<td>An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics</td>
<td>Patricia M. LoRusso, Scott A. Boerner, Lesley Seymour</td>
</tr>
<tr>
<td>1719</td>
<td>Information Needed to Conduct First-in-Human Oncology Trials in the United States: A View from a Former FDA Medical Reviewer</td>
<td>Adrian M. Senderowicz</td>
</tr>
<tr>
<td>1726</td>
<td>Approaches to Phase I Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee</td>
<td>S. Percy Ivy, Lillian L. Siu, Elizabeth Garrett-Mayer, Larry Rubinstein</td>
</tr>
<tr>
<td>1737</td>
<td>Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan</td>
<td>Martin D. Forster, Nagahiro Saijo, Lesley Seymour, Hilary Calvert</td>
</tr>
</tbody>
</table>

#### CCR Special Focus

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1756</td>
<td>GCP Data Quality for Early Clinical Development</td>
<td>Edwin P. Rock, Vernette J. Molloy, Jeffrey S. Humphrey</td>
</tr>
<tr>
<td>1764</td>
<td>The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee</td>
<td>Lesley Seymour, S. Percy Ivy, Daniel Sargent, David Spriggs, Laurence Baker, Larry Rubinstein, Mark J. Ratain, Michael Le Blanc, David Stewart, John Crowley, Susan Groshen, Jeffrey S. Humphrey, Pamela West, Donald Berry</td>
</tr>
<tr>
<td>1771</td>
<td>New Developments in Tyrosine Kinase Inhibitor Therapy for Newly Diagnosed Chronic Myeloid Leukemia</td>
<td>Philipp le Coutre, Michaela Schwarz, Theo D. Kim</td>
</tr>
<tr>
<td>1781</td>
<td>Overexpression of Smoothened Activates the Sonic Hedgehog Signaling Pathway in Pancreatic Cancer–Associated Fibroblasts</td>
<td>Kimberly Walter, Noriuki Omura, Seung-Mo Hong, Margaret Griffith, Audrey Vincent, Michael Borges, Michael Goggins</td>
</tr>
</tbody>
</table>

---

# Molecular Pathways

- **Metformin: A Therapeutic Opportunity in Breast Cancer**
  - Ana M. Gonzalez-Angulo, Funda Meric-Bernstam

- **Death Receptor Agonists as a Targeted Therapy for Cancer**
  - Jeffrey Wiezorek, Pamela Holland, Jonathan Graves

---

# CCR Special Focus

- **Phase I Clinical Trials: Overcoming Barriers**
  - Susan E. Bates

- **An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics**
  - Patricia M. LoRusso, Scott A. Boerner, Lesley Seymour

- **Information Needed to Conduct First-in-Human Oncology Trials in the United States: A View from a Former FDA Medical Reviewer**
  - Adrian M. Senderowicz

- **Approaches to Phase I Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee**
  - S. Percy Ivy, Lillian L. Siu, Elizabeth Garrett-Mayer, Larry Rubinstein

- **Performing Phase I Clinical Trials of Anticancer Agents: Perspectives from within the European Union and Japan**
  - Martin D. Forster, Nagahiro Saijo, Lesley Seymour, Hilary Calvert
IMAGING, DIAGNOSIS, PROGNOSIS

The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status
Anna M. Dahlin, Richard Palmqvist, Maria L. Henriksson, Maria Jacobsen, Vincy Eklöf, Jürgen Rutegård, Ake Öberg, and Bethany R. Van Guelpen

CANCER THERAPY: PRECLINICAL

PEA-15 Inhibits Tumorigenesis in an MDA-MB-468 Triple-Negative Breast Cancer Xenograft Model through Increased Cytoplasmic Localization of Activated Extracellular Signal-Regulated Kinase
Chandra Bartholomeusz, Ana M. Gonzalez-Angulo, Anna Kazansky, Savitri Krishnamurthy, Ping Liu, Linda X. H. Yuan, Fumiyuki Yamasaki, Shuying Liu, Naoki Hayashi, Dongwei Zhang, Francisco J. Esteva, Gabriel N. Hortobagyi, and Naoto T. Ueno

Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer

The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by Both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells
Paola Secchiero, Rebecca Voltan, Maria Grazia di Iasio, Elisabetta Melloni, Mario Tiribelli, and Giorgio Zauli

Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy
Andrew G. Sikora, Alexander Gelbard, Michael A. Davies, Daisuke Sano, Suhendan Ekmeckioglu, John Kwon, Yared Haillemichael, Padmini Jayaraman, Jeffrey N. Myers, Elizabeth A. Grimm, and Willem W. Overwijk

CANCER THERAPY: CLINICAL

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
Alan S. Wayne, Robert J. Kreitman, Harry W. Findley, Glen Lew, Cynthia Delbrook, Seth M. Steinberg, Maryalice Stetler-Stevenson, David J. FitzGerald, and Ira Pastan

Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors
Frank A. Sinicrope, Nathan R. Foster, Daniel J. Sargent, Michael J. O’Connell, and Cathryn Rankin

Value of Magnetic Resonance Spectroscopy Imaging and Dynamic Contrast-Enhanced Imaging for Detecting Prostate Cancer Foci in Men With Prior Negative Biopsy
Alessandro Sciarr, Valeria Panebianco, Mauro Ciccariello, Stefano Salecic, Susanna Cattarino, Danilo Lis, Alessandro Gentilucci, Andrea Alfalone, Silvia Bernardo, Roberto Passariello, and Vincenzo Gentile

Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia
Steven M. Kornblau, Neera Singh, YiHua Qiu, Wenjing Chen, Nianxiang Zhang, and Kevin R. Coombes
Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
Bart Kuenen, Petronella O. Witteveen, Rita Ruijter, Giuseppe Giaccone, Aruna Dontabhaktuni, Floyd Fox, Terry Katz, Hagop Yossoufian, Junming Zhu, Eric K. Rowinsky, and Emile E. Voest

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso, Smitha S. Krishnamurthi, John J. Rinehart, Lisle M. Nabell, Lisa Malburg, Paul B. Chapman, Samuel E. DePrimo, Steven Bentivegna, Keith D. Wilner, Weizhe Tan, and Alejandro D. Ricart

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer
Helen J. Ross, George R. Blumenschein, Jr., Joseph Ayers, Nevena Damjanov, Afshin Dowlati, Jennifer Garst, Nevena Damjanov, Habib Hassani, Kimberly E. Allen, Lance Leopold, Tal Z. Zaks, and Frances A. Shepherd

Mesalazine Reduces Mutations in Transforming Growth Factor β Receptor II and Activin Type II Receptor by Improvement of Replication Fidelity in Mononucleotide Repeats
Christoph Campregher, Clemens Honeder, Heekyung Chung, John M. Carethers, and Christoph Gasche

A High Proportion of DNA Variants of BRCA1 and BRCA2 Is Associated with Aberrant Splicing in Breast/Ovarian Cancer Patients
David J. Sanz, Alberto Acedo, Mar Infante, Mercedes Durán, Lucía Pérez-Cabornero, Eva Esteban-Cardenosa, Enrique Lastra, Franco Pagani, Cristina Miner, and Eladio A. Velasco

Correlation of Segmented Metabolic Tumor Volume with Outcome - Letter

Correlation of Segmented Metabolic Tumor Volume with Outcome - Response
Man Ki Chung, Chung-Hwan Baek, and Joon Young Choi,
ABOUT THE COVER

Human pancreatic cancer–associated fibroblasts (CAFs) overexpress the Hedgehog receptor SMO. Here, immunohistochemical labeling highlights overexpression of Smo protein in a human primary pancreatic adenocarcinoma. Strong Smo expression is detected in stromal fibroblasts adjacent to pancreatic cancer cells. For details, see the article by Walter and colleagues on page 1781 of this issue.
Clinical Cancer Research

16 (6)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/16/6

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.